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ransmembrane isoforms of neuregulin-1 (Nrg-1),
ligands for erbB receptors, include an extracellular
domain with an EGF-like sequence and a highly con-
served intracellular domain (ICD) of unknown function. In
this paper, we demonstrate that transmembrane isoforms of
Nrg-1 are bidirectional signaling molecules in neurons.
The stimuli for Nrg-1 back signaling include binding of
erbB receptor dimers to the extracellular domain of Nrg-1
T
 
and neuronal depolarization. These stimuli elicit pro-
teolytic release and translocation of the ICD of Nrg-1 to the
nucleus. Once in the nucleus, the Nrg-1 ICD represses
expression of several regulators of apoptosis, resulting in
decreased neuronal cell death in vitro. Thus, regulated pro-
teolytic processing of Nrg-1 results in retrograde signaling
that appears to mediate contact and activity-dependent
survival of Nrg-1–expressing neurons.
 
Introduction
 
The neuregulin-1 (Nrg-1)* gene encodes multiple isoforms
of ligands for erbB receptor tyrosine kinases (Pinkas-Kramarski
et al., 1998; Buonanno and Fischbach, 2001; Murphy et al.,
2002). Many of these Nrg-1 isoforms are membrane-anchored
 
growth factors consisting of variable NH
 
2
 
-terminal extracellular
domains (ECDs) and conserved transmembrane and COOH-
terminal cytoplasmic domains (Buonanno and Fischbach,
2001). Interactions between the ECD of Nrg-1 and erbB
receptor tyrosine kinases can occur after release of the Nrg-1
ECD, either directly after synthesis of isoforms lacking
transmembrane domains or after proteolysis of the trans-
membrane precursor form. Nrg-1–erbB interactions also can
occur within the context of cell–cell contact (Aguilar and
Slamon, 2001; Leimeroth et al., 2002). Genetic analyses
have demonstrated that Nrg-1 function is essential during
embryonic development, and have identified Nrg-1 isoform–
specific functions. Genetic disruptions in mice that prevent
expression of all Nrg-1 isoforms result in defects in cardiac
development and embryonic lethality at E10 (Lee et al., 1995;
Meyer and Birchmeier, 1995; Carraway, 1996; Kramer et al.,
1996; Liu et al., 1998a). Disruption of type III isoforms that
contain an NH
 
2
 
-terminal, cysteine-rich domain (CRD; i.e.,
CRD-Nrg-1), whose expression is restricted to the nervous
system, results in perinatal lethality (Yang et al., 1998b;
Wolpowitz et al., 2000). These neuronal CRD-Nrg-1s are
required for the formation and stable maintenance of func-
tional motor and sensory synapses.
A striking feature of the phenotype of CRD-Nrg-1
 
 
 
/
 
 
 
mice is the progressive loss of the motor and sensory neurons
that would normally express the CRD-Nrg-1 growth factor
(Wolpowitz et al., 2000). In CRD-Nrg-1
 
 
 
/
 
 
 
 mice, neuron
loss occurs only after the neurons enter target fields. In the
target fields, these neurons initiate the formation of contacts,
but fail to sustain synaptic interactions. Thus, it appears that
CRD-Nrg-1 interactions with erbB receptors elicit a signal
required for the survival of the CRD-Nrg-1–expressing cell.
The nature and origin of this signal is unknown. One possi-
bility is that CRD-Nrg-1 activation of erbB signaling stimulates
the release of a soluble factor that interacts with receptors on
the surface of neurons. An alternative explanation is that a
CRD-Nrg-1–erbB complex signals bidirectionally via erbB
kinase activity in the “forward” direction and the CRD-Nrg-1
intracellular domain (ICD; i.e., Nrg-1-ICD) in the “reverse”
direction. Several lines of evidence support a signaling function
for the Nrg-1-ICD. First, ectopic expression of Nrg-1 leads
to Nrg-1-ICD–dependent apoptosis (Grimm and Leder,
1997; Grimm et al., 1998; Weinstein and Leder, 2000).
Second, the Nrg-1-ICD forms specific complexes with cyto-
plasmic proteins, including LIM kinase (Wang et al., 1998)
and a zinc finger protein of undetermined function (the
cytoplasmic domain of Nrg-interacting protein [CNIP];
unpublished data). Third, the Nrg-1-ICD is required for
Nrg-1 function in vivo (Liu et al., 1998a).
In this paper, we set out to address two questions. First,
does interaction of cell surface CRD-Nrg-1 with erbB4
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ligand binding domain directly stimulate a survival signal
in neurons? Second, do these interactions stimulate pro-
teolytic release of a functional Nrg-1-ICD? We demon-
strate that treating CRD-Nrg-1–expressing neurons with
soluble forms of erbB ECDs promotes neuron survival in
vitro and alters the expression of several apoptotic genes.
Depolarization of the neurons appears to regulate gene ex-
pression in a similar manner, and either depolarization or
treatment with soluble erbBs elicits translocation of the
Nrg-1-ICD to the nucleus. Using transfected cells, we also
demonstrate that the Nrg-1-ICD contains an amino acid
motif required for nuclear targeting, that the Nrg-1-ICD
has the ability to function as a transcriptional transactiva-
tor, and that compounds that inhibit 
 
 
 
-secretase activity al-
ter the processing of the Nrg-1-ICD.
 
Results
 
Previously, we documented loss of CRD-Nrg-1–expressing
motor and sensory neurons and cranial nerve nuclei in
CRD-Nrg-1
 
 
 
/
 
 
 
 mice (Wolpowitz et al., 2000). Loss of
CRD-Nrg-1–expressing neurons in spiral ganglia (Fig. 1 A)
and hippocampus (not depicted) also was evident in E16
CRD-Nrg-1
 
 
 
/
 
 
 
 embryos. The fraction of the spiral ganglion
volume and the CA3 region of the hippocampus occupied
by neurons in wild-type or CRD-Nrg-1
 
 
 
/
 
 
 
 embryos were
evaluated from 12-
 
 
 
M serial sections stained for GAP43 ex-
pression. The fraction of neurons in mutant hippocampus
(CA3 region) and mutant spiral ganglia (SG) were decreased
by 50 and 90%, respectively (Fig. 1 A and not depicted). In
contrast, evaluation of the erbB4-expressing cells within the
target cochlea revealed that neither the number nor the dis-
tribution of erbB4-expressing cells (Co) was altered in mu-
tant embryos (compared with wild-type; Fig. 1 A, top).
The observations that disrupting the CRD-Nrg-1 gene re-
sulted in the loss of neurons that would have expressed
CRD-Nrg-1 protein, led us to ask whether interactions be-
tween erbB receptors and CRD-Nrg-1 promotes neuronal
survival. To test this idea, neurons were isolated from E16
mouse embryos, dispersed, and maintained in vitro. Apop-
tosis was evaluated by the presence of nuclear shrinkage and
chromatin condensation after staining with bisbenzimide
(Fig. 1 B, arrows). The fraction of neurons that were under-
going apoptosis 48 h after plating was 0.19–0.22 (Fig. 1, B
and C, untreated and Nrg-ECD–treated controls). When
neurons were incubated overnight in media containing solu-
ble forms of the ECDs of erbB2 and erbB4 (which, together,
constitute a high affinity receptor for Nrg-1; Fitzpatrick et
al., 1998), the number of apoptotic neurons was reduced
significantly (Fig. 1 C; *, P 
 
  
 
0.01). The protection against
apoptosis was specific for erbB2:erbB4. Neither soluble
erbB2 alone (which does not bind Nrg-1) nor the soluble
erbB2:erbB4 preincubated with CRD-Nrg-1-ECD before
treatment affected neuronal survival (fraction of apoptotic
neurons: untreated controls, 0.21; CRD-Nrg-1-ECD, 0.20;
erbB2:B4, 0.13; erbB2:B4 
 
 
 
 CRD-Nrg-1-ECD, 0.17).
Treatment with soluble erbBs also protected hippocampal
neurons from staurosporine-induced apoptosis by 
 
 
 
50%
(fraction apoptotic: untreated controls 0.2; staurosporine
alone 0.62; staurosporine 
 
 
 
 erbB2:B4 0.38). In addition to
the changes in the number of healthy versus dying neurons
detected under these conditions, there were parallel changes
in the percentage of cells with detectable immunoreactive
Nrg-1-ICD, and the intensity of staining in general, and
over nuclei in particular.
The apparent differences in localization and levels of Nrg-1
in erbB2:erbB4-treated cells were examined in greater detail
(Fig. 2). Neuronal cultures were stained with antibodies rec-
ognizing the shared ECD of Nrg-1 or the COOH-terminal
region of the longest ICD of Nrg-1 (Nrg-1-ICD; a-form).
Both antibodies against Nrg-1-ECD and Nrg-1-ICD stained
untreated cells in an overlapping distribution in all nonnu-
clear compartments. Immunoreactive Nrg-1 was more dif-
fusely distributed in neuronal soma and along the processes
of control neurons viewed at either the nuclear (Fig. 2 A, top
left) or the neurite level (Fig. 2 A, bottom). Nonneuronal
cells did not stain with Nrg-1 antibodies, and all immuno-
staining was completely blocked by preincubation of the an-
tibodies with peptide antigen (Fig. 2 D). After treatment
Figure 1. Interaction between CRD-Nrg-1 and erbB receptors 
enhances survival of CRD-Nrg-1–expressing neurons. (A) Spiral 
ganglion neurons are lost after genetic disruption of CRD-Nrg-1. 
Spiral ganglia from wild-type (left) or CRD-Nrg-1
 /  mutant (right) 
E16.5 mouse embryos were hybridized to cRNA probes for 
either erbB4 (top) or GAP43 (to identify neurons). Based on 3-D 
reconstructions of serial sections, there was a 90% decrease in spiral 
ganglion neurons (GAP43 mRNA positive; SG) in mutant embryos. 
The erbB4-expressing cochlear epithelium (Co) was not measurably 
affected in the mutants. (B and C) Dispersed neurons were maintained 
in culture for 2 d and treated with soluble erbB2   erbB4 (erbB2:
B4), the CRD-Nrg-1 ECD (Nrg-ECD), a mixture of soluble erbB2:4 
and Nrg-ECD, or staurosporine with or without soluble erbB2:B4. 
Apoptotic cells were visualized by staining nuclei with bisbenzimide 
(B, arrows). The percentage of total nuclei ( SEM) that appeared 
apoptotic was quantified in 10 fields from each treatment group in 
three independent experiments. Where indicated, values differed 
significantly (P   0.01) from the untreated control group (*) or from 
the staurosporine-treated group (**).T
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with soluble erbB2:B4, the Nrg-1 staining pattern changed
in several ways. First, there was a decrease in diffuse staining
along processes with both the extracellular and ICD antibod-
ies. Second, diffuse staining was replaced by pronounced
“patches” of immunoreactive Nrg-1 at various points along
the processes. Third, there was an increase in somal staining,
in particular of a Golgi-like area adjacent to nuclei. The
patches and the Golgi-like staining were seen with both anti-
bodies; and fourth, multiple discrete puncta were seen in nu-
clei (note that in Fig. 2 A, all images are from 1-
 
 
 
M sections
captured through the middle of the nucleus, except for the
neurite pictures in the bottom). These puncta stained with
ICD antibody, but not with ECD antibody. Thus, within 20
min after treatment with soluble erbB2:erbB4, the intracellu-
lar and the ECDs separated and the ICD entered the nucleus.
The presence of strong patches of Nrg-1-ICD, but not
Nrg-1-ECD, immunoreactivity in neuronal nuclei indicates
that exposing neurons to soluble erbB2:erbB4 resulted in
Figure 2. Interaction with erbB receptors, or depolarization, target Nrg-1-ICD to the nucleus in primary neurons. (A) Dispersed E16 spiral 
ganglion neurons were maintained in vitro for 3 d and stained with antibodies recognizing the ICD of the “a” form of Nrg-1 (red), or the ECD 
of all Nrg-1  isoforms (green). Nuclei were stained with DAPI (blue). 15 min before fixation and staining, neuronal cultures were either 
untreated (control) or treated with soluble erbB2:B4 (serbB2:B4). Fluorescent images in 1- m sections were collected with a two-photon 
microscope. Under control conditions, intracellular and ECDs colocalize in soma and in processes. After treatment, colocalization is lost in 
neurites, both domains appear in clusters, and clusters of ICD staining are clearly present in the nucleus. The top six images are from 1- m 
optical sections collected from the middle of the nuclei, whereas the bottom two images were collected at a level below the nuclei to emphasize 
the distribution of Nrg-1 in the processes. (B) The percentage of neuronal nuclei showing staining with the antibody recognizing the Nrg-1-ICD 
was quantified after a 15-min treatment with nothing (control), soluble erbB2 (which does not bind to Nrg-1), soluble erbB2   erbB4 (erbB2:B4), 
or 50 mM KCl. Only cells showing clearly outlined nuclei were included in the analyses and at least 50 cells were scored per field. The data 
are plotted as the mean of the counts from two experiments. (C) Spiral ganglion neurons from six E13.5 embryos were maintained in culture 
overnight before treatment for 15 min with nothing (control), soluble erbB2 (B2), soluble erbB2   erbB4 (B2:B4), or 50 mM KCl. Nuclear 
extracts (18  g protein/lane) were resolved by SDS-PAGE, and Nrg-1-ICD was detected by probing immunoblots with the ICD antibody 
(sc-348). After stripping, the filters were reprobed sequentially with antibodies recognizing histone H1 (H1, nuclear marker) or the translation 
initiation factor eIF5 (eIF5, cytoplasmic marker). The anti–Nrg-1-ICD antibody recognized a protein of  50 kD. Nuclei from cells treated with 
soluble erbB2:B4 or 50 mM KCl had significantly elevated levels of this 50-kD band. (D) Spiral ganglia neurons were treated for 15 min with 
soluble erbB2   erbB4 and were either fixed and stained with antibody recognizing the Nrg-1-ICD (left) or lysed and analyzed by immunoblotting 
(right). Where indicated ( peptide,  pept), the primary antibody was preincubated with immunizing peptide before staining cells or probing 
filters. Preincubation eliminated staining of cells and staining of the 50-kD protein on immunoblots ( pept).T
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physical separation of Nrg-1 ECD from Nrg-1 ICD. We
postulated that such separation and subsequent nuclear tar-
geting of the Nrg-1-ICD might participate in Nrg-1:erbB-
induced signaling, which is implicated in the survival of neu-
rons in vivo (Wolpowitz et al., 2000) and in vitro (Fig. 1).
To verify, and to quantify the magnitude of this response,
we measured the percentage of total neurons that had nu-
clear, immunoreactive Nrg-1-ICD under a variety of condi-
tions. In untreated (control) cultures, 15–20% of neuronal
nuclei were positive for Nrg-1-ICD staining. After 15 min
of treatment with soluble erbB2:erbB4 or after 15 min of de-
polarization (see Materials and methods), 
 
 
 
85% of nuclei
stained positive for Nrg-1-ICD (Fig. 2 B). Treatment with
soluble erbB2 alone did not affect nuclear staining.
To explore further the possibility that cell surface erbB–
CRD-Nrg-1 interactions result in proteolytic release and nu-
clear translocation of the Nrg-1-ICD, we prepared nuclear
fractions from dispersed neurons 15 min after treatment
with erbB2, erbB2 
 
  
 
erbB4, or 50 mM KCl. Extract pro-
teins were resolved electrophoretically and immunoblots
were probed with the Nrg-1-ICD specific antibody (Fig. 2
C). A faint signal at 
 
 
 
50 kD was seen in nuclear extracts
from untreated (control) or soluble erbB2-treated cells.
Stimulation with either the soluble erbB2:erbB4 combina-
tion or with KCl elevated the amount of the 
 
 
 
50-kD band
detected in nuclear extracts. Preincubating the antibody
with immunizing peptide (Nrg-1 
 
 
 
 pept) led to a loss of sig-
nal (Fig. 2 D). The size of this band is consistent with a pep-
tide corresponding to the intracellular portion of Nrg-1a
(see Fig. 4; for review see Wang et al., 2001).
These results are consistent with regulated cleavage and
release of the Nrg-1-ICD from the membrane and its subse-
quent translocation to the nucleus. Regulated intramembra-
nous proteolysis of Notch (Struhl and Adachi, 2000; Struhl
and Greenwald, 2001), SRE-BP1 and 2 (Brown and Gold-
stein, 1997; Brown et al., 2000), and possibly 
 
 
 
APP (Cao
and Sudhof, 2001; Kimberly et al., 2001) and erbB4 (Ni et
al., 2001; Lee et al., 2002) result in ICD-dependent regula-
tion of gene expression. To determine whether regulated
nuclear targeting of the Nrg-1-ICD was associated with
changes in gene expression, we isolated total RNA from neu-
ronal cultures that were either untreated or treated for 2 h
with soluble erbB2 
 
 
 
 erbB4. Using these RNAs, we synthe-
sized 
 
32
 
P-labeled cDNAs and probed a mouse cDNA array.
Clear differences in expression of Oct-3, p19
 
INK4
 
, IL-11,
Bcl-X, BAK, and RIP were seen and confirmed by RT-PCR
(Fig. 3). Expression of Bcl-X, BAK, and RIP were repressed
after treatment with the soluble erbBs and after depolariza-
tion with KCl. Expression of Oct-3, p19
 
INK4
 
, and IL-11 in-
creased after treatment of neurons with erbB2 
 
 
 
 erbB4, but
only Oct-3 expression increased in response to KCl. Thus,
although both depolarization and erbB2:erbB4 treatment
induced nuclear translocation of Nrg-1-ICD, the effects of
these treatments on target gene expression differed.
To confirm that the effects on gene expression seen after
treatment of neuronal cultures with soluble erbB2 
 
 
 
 erbB4
required the interaction of these proteins with the ECD of
endogenously expressed Nrg-1, neuronal cultures were ei-
ther untreated, treated with soluble erbB2 
 
 
 
 erbB4, or
treated with erbB2 
 
 
 
 erbB4 that had been preincubated
with the CRD-Nrg-1 ECD. Expression of BAK and p19
 
INK4
 
were measured by RT-PCR analysis of total RNA. Preincu-
bating erbB2 
 
 
 
 erbB4 with CRD-Nrg-1 ECD blocked the
effects on BAK and p19
 
INK4
 
 expression (Fig. 3).
To gain more insight into the dynamics of regulated nu-
clear targeting of the Nrg-1-ICD, we expressed a series of
chimeric CRD-Nrg-1s in HEK 293T cells (Fig. 4). Subcel-
lular targeting of Nrg-1 was followed in living cells trans-
fected with a CRD-Nrg-1
 
 
 
a-GFP fusion protein by contin-
uous monitoring of the distribution of GFP by collecting
images through the z-axis of cells (Fig. 4 A). In control cells,
the strongest CRD-Nrg-1-GFP signal was detected around
the cell periphery and in a single intracellular region, consis-
tent with previous reports of Nrg-1 localization in the
plasma membrane, Golgi structure, and endoplasmic reticu-
lum (Burgess et al., 1995). This pattern remained essentially
unchanged for up to 2 h of continuous observation. In con-
trast, within 2–4 min after treatment with soluble erbB2 
 
 
 
erbB4, the distribution of green fluorescence changed and
distinct fluorescent aggregates were seen both in peripheral
regions of the cells and near Golgi-like structures. By 16 min
after erbB2:erbB4 treatment, these GFP aggregates moved
along discrete paths and entered the nucleus (Fig. 4, arrows).
Figure 3. Treatments that target Nrg-1-ICD to the nucleus alter 
gene expression. E13.5 spiral ganglion neurons maintained in culture 
overnight were untreated (control) or stimulated with soluble erbB2:B4 
or 50 mM KCl for 2 h. Total RNA was isolated and the relative levels 
of Bcl-XL, RIP, BAK, p19
INK4, Oct-3, and actin mRNAs were determined 
by RT-PCR. Amplified products were resolved on agarose gels and 
visualized with ethidium bromide. Arrows indicate amplified products 
whose identities were verified by DNA sequencing (the additional 
bands in the treated BAK lanes and the untreated Oct-3 lanes were 
nonspecific amplification products). This experiment was repeated 
with soluble erbB2:B4 that had been preincubated with the ECD of 
CRD-Nrg-1 (right).T
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The induced targeting of Nrg-1-ICD to the nucleus indi-
cated that the Nrg-1-ICD might contain an identifiable
NLS. Inspection of the primary sequence of Nrg-1-ICDs
identified two potential NLSs (http://psort.nibb.ac.jp). The
first, NLS-1, includes the first eight amino acids after the
transmembrane domain (KTKKQRKK) and is found in all
Nrg-1-ICDs. We expressed Nrg-1-ICD-GFP fusion pro-
teins that contained or lacked these eight amino acids in
293T cells (Fig. 4 B; these fusion proteins included just the
ICD of Nrg-1 fused to GFP and lacked the transmembrane
domain). Strong nuclear and diffuse cytoplasmic staining
was seen when Nrg-1
 
 
 
c-ICD-GFP was expressed. Nrg-1
 
 
 
c-
ICD
 
 
 
NLS1
 
-GFP, lacking the eight–amino acid NLS, was dis-
tributed diffusely throughout the cells and did not concen-
trate in nuclei, which is consistent with a requirement for
this domain for accumulating Nrg-1-ICD in nuclei. The
presence or absence of the second putative NLS (PRL-
REKK) had no effect on the cellular localization of GFP fu-
sion proteins (unpublished data).
To test further that erbB2:erbB4-induced nuclear targeting
of Nrg-1a-ICD was associated with proteolysis of the full-
length transmembrane form of Nrg-1, we separated cyto-
plasmic and membrane fractions from nuclear extracts of
HEK293T cells expressing a CRD-Nrg-1
 
 
 
a-HA fusion pro-
tein (full-length CRD-Nrg-1
 
 
 
a tagged at the COOH termi-
nus with an 11–amino acid HA epitope). The Nrg-1 COOH
terminus was detected by probing immunoblots with an anti-
HA antibody. In cells incubated under control conditions
(untreated or treated with soluble erbB2; Fig. 4 C, erbB2),
the 
 
 
 
110-kD full-length protein and several higher molecu-
lar mass bands were detected. These higher molecular mass
bands likely correspond to highly glycosylated or possibly ag-
gregated forms of Nrg-1(Wang et al., 2001). Treatment of
transfected cells with soluble erbB2 
 
 
 
 erbB4 resulted in in-
creased amounts of a mostly nuclear 
 
 
 
50-kD protein corre-
sponding to the Nrg-1-ICD (Fig. 4 C, erbB2:B4).
As a further demonstration that the Nrg-1-ICD translo-
cates into nuclei, we expressed fusion proteins comprised of
CRD-Nrg-1
 
 
 
a and the chimeric transcription factor Gal4-
VP16 (Nrg-1
 
 
 
a-Gal4-VP16), Nrg-1
 
 
 
a-ICD (lacking the
ECD and the transmembrane domains) plus the DNA-
binding domain from Gal4 (ICD-Gal4), but without the
VP16 activation domain, or Nrg-1
 
 
 
a-ICD
 
 
 
NLS
 
 plus the
Gal4 DNA-binding domain (ICD
 
 
 
NLS
 
-Gal4). The distribu-
tion of these fusion proteins in HEK 293T cells was mea-
sured by assaying luciferase expression from a cotransfected
 
Figure 4.
 
Nuclear translocation of Nrg-1-ICD–GFP fusions can be 
visualized in living cells.
 
 (A) The schematic illustration at the 
top shows the NRG-1
 
 
 
a-GFP chimeric used in this work. ECD, 
extracellular domain; TM, transmembrane domain; NLS1, the putative 
nuclear localization sequence (B); ICD, intracellular domain; GFP, 
green fluorescent protein. Intracellular movement of NRG-1
 
 
 
a-GFP 
was followed in live cells (HEK 293 cells) by two-photon microscopy. 
Images (1 
 
 
 
m from the middle of the nucleus) were collected at various 
intervals (min) after treatment with soluble erbB2 
 
 
 
 erbB4. The arrows 
in the enlargement point out puncta of Nrg-1-GFP that have entered 
the nucleus. (B) HEK293 cells were transfected with plasmids encoding 
either an intact Nrg-1-ICD fused to GFP (top) or an Nrg-1-ICD lacking 
the putative NLS fused to GFP (bottom). The subcellular localization 
of the fusion proteins was followed by conventional fluorescence 
microscopy. At left are phase images. In the middle, the green 
fluorescence signal is shown (arrows point to positive cells), and at 
the right, both green fluorescence and DAPI staining are shown. 
(C) Cytoplasmic (Cyto) and nuclear (Nuc) fractions were prepared 
from mock-transfected or NRG-1
 
 
 
a-HA (HA, influenza virus 
hemagglutinin-derived epitope added to COOH terminus of Nrg-
1)–transfected HEK293T cells. Proteins were analyzed by immunoblot-
ting using antibodies recognizing the HA epitope. NRG-1
 
 
 
a-HA–
transfected cells were treated for 15 min with erbB2 (32 
 
 
 
g/ml) or 
erbB2:4 (32 
 
 
 
g/ml). In addition to a doublet of nonspecific bands, 
proteins of 
 
 
 
100 kD (full-length and aggregated NRG-1
 
 
 
a) and 50 kD 
(ICD-HA) were detected. The 50-kD band enriched in the nuclear 
fraction was only seen in cells treated with soluble erbB2:B4.T
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Gal4-UAS–luciferase reporter plasmid (Fig. 5). Expression
of the nonmembrane-tethered Nrg-1-ICD-Gal4
 
DBD
 
 chimera
increased luciferase activity 
 
 
 
10-fold compared with the
full-length Nrg-1 fused to Gal4-VP16 or compared with
Nrg-1-ICD
 
 
 
NLS
 
-Gal4
 
DBD
 
 (Fig. 5 B; 33-fold vs. fourfold
or 2.8-fold, respectively). This level of transactivation is
roughly comparable to the levels seen in cells expressing a
Gal4
 
DBD
 
-VP16
 
AD
 
 chimera. As the Gal4
 
DBD
 
 lacks a transacti-
vation domain and a nuclear localization signal, luciferase
activity indicates that the Nrg-1-ICD has an interaction do-
main that is able to recruit coactivators to the Gal4-UAS
promoter. 
The appearance of a 
 
 
 
50-kD COOH-terminal fragment
of Nrg-1 in nuclei after soluble erbB2:erbB4 (Fig. 2 C and
Fig. 4 C) or after depolarization (Fig. 2 C) is consistent with
regulated cleavage of the transmembrane precursor form of
CRD-Nrg-1. Constitutive and regulated extracellular cleav-
age of both type 1 and type III Nrg-1 has been characterized
(Burgess et al., 1995; Lu et al., 1995; Liu et al., 1998b; Loeb
et al., 1998; Han and Fischbach, 1999; Montero et al.,
2000; Wang et al., 2001), but events leading to the release of
the Nrg-1-ICD from the membrane have not been studied.
Because the first eight intracellular amino acids are required
for nuclear translocation, the cleavage event that releases the
ICD is expected to occur at the junction between this se-
quence and the transmembrane domain, or within the trans-
membrane domain. As such, we tested whether 
 
 
 
-secretases,
enzymes known to catalyze intramembranous proteolysis
(Struhl and Adachi, 1998, 2000; Struhl and Greenwald,
1999, 2001; Brown et al., 2000; Ni et al., 2001; Ebinu and
Yankner, 2002; Lee et al., 2002), might be involved in Nrg-
1-ICD processing. HEK 293T cells expressing CRD-Nrg-
1
 
 
 
a-Gal4-VP16 were pretreated with 
 
 
 
-secretase inhibitors
(Fig. 5; inhibitors 1, CM-265; 2, WPE(III)-36B; or 3, MW
(III)-26A) for 8 h before treatment with soluble erbB2 
 
 
 
erbB4. In the absence of inhibitors, or in cells treated with
an inactive analogue of these inhibitors (JT-326), exposure
of cells to soluble erbB2:erbB4 significantly elevated lu-
ciferase levels (Fig. 5 C, columns 3 and 9 compared with
columns 1, 2, or 5). The induction of luciferase expression
was blocked by all three inhibitors, as well as by preincubat-
ing soluble erbB2:erbB4 with the CRD-Nrg-1 ECD. There-
fore, the stimulated nuclear targeting of the CRD-Nrg-
1-ICD, at least in part, is dependent on a 
 
 
 
-secretase–like
activity. These results are consistent with a model in which
CRD-Nrg-1–erbB interactions result in cleavage of Nrg-1
within the transmembrane domain and the subsequent re-
lease and nuclear targeting of the Nrg-1-ICD.
 
Discussion
 
The principle finding of our studies is that CRD-Nrg-1 is a
bidirectional signaling molecule. Interaction of the Nrg-1
ECD with erbB receptors results in well-characterized sig-
naling in the erbB-expressing target cells. In neurons, Nrg-1
processing and Nrg-1-ICD nuclear targeting are regulated
by either interaction with erbB2–erbB4 or by depolariza-
tion, and results in altered gene expression. Stimulated nu-
clear translocation of Nrg-1-ICD depends on an activity
that is sensitive to 
 
 
 
-secretase inhibitors. It is striking that in
our original cDNA screen we found that four of the six tar-
get genes encode products involved in either apoptosis or in
cell cycle progression, and that nuclear targeting of the Nrg-
1-ICD prevents neuronal apoptosis. Together, these results
Figure 5. Treatment of transfected cells with soluble erbB receptors 
stimulates Nrg-1-ICD cleavage and translocation to a transcriptionally 
active compartment. (A) Schematic illustrations showing organization 
of the Gal4-Nrg-1 fusion proteins used. Gal4, DNA-binding domain; 
VP16, activation domain from the Herpes virus VP16 transcription 
factor. (B) Nrg-1 a-Gal4-VP16, Nrg-ICD-Gal4DBD, Nrg-ICD NLS-
Gal4DBD, Nrg-1-ICD, or Gal4DBD-VP16AD expression plasmids or 
empty vector (control) were cotransfected into HEK293T cells with 
a reporter plasmid containing four copies of the Gal4 UAS fused to 
the luciferase coding region. Luciferase activities were measured 48 h 
after transfection and values normalized to the control levels ( SEM). 
Membrane tethering (Nrg-1-Gal4-VP16) or exclusion from the nucleus 
(Nrg-1-ICD NLS-Gal4DBD) reduced the Nrg-1-ICD-Gal4 transcriptional 
activity by over 10-fold. (C) The NRG-1 a-Gal4-VP16–expressing 
plasmid was cotransfected into HEK293T cells with the Gal4-UAS–
luciferase reporter. Cells were treated with one of three  -secretase 
inhibitors or an inactive analogue of these inhibitors from 24–48 h 
after transfection. For the final 8 h before measuring, luciferase activity 
cells also were treated with soluble erbB2, soluble erbB2   erbB4 
(erbB2:B4), erbB2:B4 preincubated with the ECD of CRD-Nrg-1 
(NRG-ECD), or CRD-Nrg-1 ECD alone. Luciferase levels ( SEM) 
were normalized to control (untreated cells cotransfected with reporter 
and Nrg-1-Gal4-VP16 plasmids   1).T
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support the proposal that erbB–Nrg-1 interactions elicit a
Nrg-1-ICD signaling cascade important to neuronal sur-
vival. This proposed signaling mechanism could explain the
loss of Nrg-1–expressing neurons that have been consis-
tently reported in mice in which all, or part, of the Nrg-1
gene has been disrupted (Kramer et al., 1996; Erickson et
al., 1997; Meyer et al., 1997; Britsch et al., 1998; Wolpo-
witz et al., 2000).
Our current working model of CRD-Nrg-1 signaling is
schematized in Fig. 6. Transmembrane Nrg-1 and erbB re-
ceptors are expressed on the surface of neighboring cells. Af-
ter binding to the Nrg-1 EGF-like domain, erbB4 (predomi-
nantly on target neurons or erbB3 on glia—not depicted for
simplicity) dimerizes, most likely with erbB2 (Fig. 6, steps 1
and 2). As a result, the erbB receptors are activated and for-
ward signaling occurs (Fig. 6, step 6). In addition, formation
of this complex results in cleavage of Nrg-1, possibly in both
the external juxtamembrane region releasing the EGF-like
domain (Fig. 6, step 3), and in the transmembrane domain
(Fig. 6, step 4). The details of the cleavage events are unclear.
To date, we have focused our studies on CRD-Nrg-1 and
not Ig-Nrg-1. The processing of transmembrane CRD- and
Ig-Nrg-1 differs. The CRD domain provides a second mem-
brane interaction domain (Wang et al., 2001; Cabedo et al.,
2002). Recent results in transfected cells indicate that CRD-
Nrg-1 initially presents in a hairpin-like configuration at the
cell surface with both the NH2 terminus and COOH termi-
nus in the cytoplasm, with part of the CRD domain forming
an NH2-terminal transmembrane domain. Cleavage in the
“stalk” region yields two molecules, each with a single trans-
membrane domain (Wang et al., 2001). In this scenario, the
EGF-like domain that interacts with the erbB receptors and
the ICD implicated in back signaling are parts of separate
polypeptides. If this topology is dominant in neurons, then
these two polypeptides must remain physically associated if
EGF-like domain binding to erbB receptors is to elicit pro-
teolysis in the second transmembrane domain. The results of
double staining of neurons with antibodies recognizing ei-
ther the ECD or the ICD, of Nrg-1 (Fig. 2 A) and subcellu-
lar fractionation data support this conclusion. Before treat-
ment with soluble erbB2   erbB4, the Nrg-1 extracellular
and ICDs colocalize on neuronal processes. After treatment,
both domains cluster and the intracellular clusters occupy
new positions distinct from the ECDs.
Although Ig-Nrg-1 can signal as transmembrane proteins
(Aguilar and Slamon, 2001), the Ig-EGF–like ECD is readily
released from the transmembrane precursor, both under basal
conditions and in response to activation of PKC and MAPK
(Loeb et al., 1998; Han and Fischbach, 1999; Wang et al.,
2001). At present, we do not know whether Ig-Nrg-1 is in-
volved in back signaling, and if so, whether the same biologi-
cal response is elicited. It is noteworthy that ectopic expres-
sion of transmembrane Ig-Nrg-1 in nonneuronal cells, in
vitro and in vivo, increases apoptosis and that the apoptotic
response is ICD-dependent (Grimm and Leder, 1997;
Grimm et al., 1998; Weinstein et al., 1998; Weinstein and
Leder, 2000). Whether the pro- versus antiapoptotic signals
represent differences in cell types studied or differences in Ig-
versus CRD-Nrg-1 back signaling is not known.
After cleavage and release from the plasma membrane, the
Nrg-1-ICD translocates to the nucleus (Fig. 6, step 5). This
nuclear translocation is associated with changes in gene
expression and cellular phenotype. As a component of a
Gal4DBD-Nrg-1-ICD fusion protein, the Nrg-1-ICD has
transcriptional transactivation activity (Fig. 5). Whether this
is a true property of the Nrg-1-ICD or simply a consequence
of the presence of protein interaction domains within the
Nrg-1-ICD that allows the fusion protein to interact with
bona fide transactivators, is not known. Examination of the
Nrg-1-ICD sequence failed to identify any obvious DNA-
binding or transcriptional activation motifs, and the ques-
tion of whether this protein has inherent transcriptional reg-
ulatory properties needs to be addressed experimentally.
Within the context of our working model, we propose that
Nrg-1-ICD physically interacts with an unidentified tran-
scription factor, either before entering the nucleus (Fig. 6,
step 5 b) or in the nucleus (Fig. 6, step 5 c).
Although the model depicted in Fig. 6 implies that all
back signaling that is transduced by the Nrg-1-ICD involves
nuclear translocation, we cannot rule out other nonnuclear
targets for the released Nrg-1-ICD. Two possible binding
partners for the Nrg-1-ICD that have been described in-
clude LIM kinase 1 (LIMK1; Wang et al., 1998) and a sec-
ond zinc finger–containing protein related to PLZF (CNIP;
unpublished data). The Nrg-1-ICD–LIMK1 interaction is
believed to occur at synapses where LIMK1 is involved in
regulating actin reorganization and neurite outgrowth (Ar-
ber et al., 1998; Wang et al., 1998, 2000; Yang et al., 1998a;
Aizawa et al., 2001). LIMK1 also shuttles between the nu-
Figure 6. Bidirectional signaling by transmembrane Nrg-1. Both 
forward and back signaling result from interactions between erbB 
receptors (blue) and membrane-tethered Nrg-1 (green and red). 
Interaction (steps 1 and 2) results in activation of erbB receptor 
tyrosine kinases and subsequent induction of target genes (step 6) 
in erbB-expressing cells, as well as intramembranous (and possibly 
extracellular) cleavage of Nrg-1 (steps 3 and 4). The released Nrg-1-
ICD (red) translocates from neurites to cell bodies (step 5a), and 
then to the nucleus, possibly with other proteins (step 5b), where 
it regulates target gene expression (step 5c). See the Discussion for 
further details of this model.T
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cleus and cytoplasm (Yang and Mizuno, 1999), and is
linked, via the actin cytoskeleton, to transcriptional regula-
tion (Geneste et al., 2002). Whether Nrg-1-ICD interac-
tions affect LIMK1 function, or whether LIMK1 is a signifi-
cant component of the Nrg-1-ICD back-signaling pathway,
is not known.
A number of recent papers have added to the growing list
of transmembrane proteins that have ICDs released by regu-
lated intramembranous proteolysis (Brown and Goldstein,
1997; Brown et al., 2000; Jeffries and Capobianco, 2000;
Ebinu and Yankner, 2002; Lee et al., 2002; Leissring et al.,
2002). Based on our results, CRD-Nrg-1 should be ad-
ded to this list. In the nervous system, CRD-Nrg-1 (or Ig-
Nrg-1) and erbB4 (and possibly erbB3) constitute a bidi-
rectional signaling module, reminiscent of other proteins
involved in neuronal development and function, notably
ephrin B ligands and Eph receptors (Lu et al., 2001;
Schmucker and Zipursky, 2001). What is apparently unique
to the CRD-Nrg-1–erbB4 system is the coupling of classical
receptor tyrosine kinase signaling in one direction with the
regulated release of a transcriptional regulator from a mem-
brane-tethered precursor in the other direction.
Materials and methods
Neuronal cultures
All culture media and supplements were purchased from GIBCO BRL. Spi-
ral ganglia from E13–E16 mouse embryos were dissociated mechanically
into a single cell suspension after digestion with trypsin. The cells were re-
covered by centrifugation (1,000 g for 8 min) and the pellet resuspended in
culture medium consisting of Neurobasal-A medium supplemented with
B-27 and 0.5 mM L-glutamine. The suspension was seeded on a 6-ml dish
or laminin-coated (0.01 mg/ml) plastic coverslips at 400,000 cells/ml. For
the hippocampal neuronal culture, the hippocampus was dissected from
E16 mouse brain and dispersed after trypsin digestion. Cells were plated
(150,000 cells/6-cm plastic petri dish) in neurobasal medium. Cultures
were maintained at 37 C in an atmosphere containing 5% CO2.
Soluble erbB receptors were prepared by transfecting HEK293 cells with
plasmids encoding chimeras between human erbB2 (residues 20–645) or
erbB4 (26–640) and the Fc domain of human IgG (Genentech, Inc.). After
48 h, conditioned media were collected and either concentrated and used
as such, or fusion proteins were purified using protein A–agarose. Purity
and concentrations were assessed by immunoblotting and silver staining
after separation of 7.5% SDS–polyacrylamide gels. Soluble erbB2 and
erbB4 were used at  10  g/ml final concentrations.
Analysis of gene expression
Total RNA isolated from untreated and soluble erbB2   erbB4–treated
E13.5 cultures of sensory neurons of spiral ganglia, was labeled with 
32P
using the Atlas Pure Total RNA Labeling System (CLONTECH Laboratories,
Inc.) and hybridized to Atlas Mouse 1.2 arrays (CLONTECH Laboratories,
Inc.). After a high stringency wash and autoradiography, differences be-
tween the two hybridization patterns were noted. Total RNA from E13.5
SGN cultures was used for RT-PCR. PCR reactions were performed for 35
cycles (45 s at 94 C, 60 s at 52 C, and 90 s at 72 C) in a volume of 25  l
containing 1  PCR buffer, 100  M dNTPs, 1  M each primer, and 1 U
Taq polymerase (Boehringer). Reactions were done in triplicate. Amplified
products were separated on 3% NuSeive agarose gels and the band inten-
sity was compared with amplified actin bands. Samples processed in par-
allel, but without reverse transcriptase added were used as negative con-
trols. In initial experiments, amplified bands were purified and sequenced
to confirm their identity.
Immunostaining
Neuronal cultures were fixed with 4% PFA and 4% sucrose in PBS for 15
min, and permeabilized with 0.25% Triton X-100 in PBS for 5 min. The
cells were washed three times in PBS and incubated in 10% normal goat
serum for 1 h at 37 C. Cells were incubated overnight at 4 C in primary
antibodies in PBS with 3% normal goat serum (Nrg-ICD, 1:1,000, sc-348
or sc-537 [Santa Cruz Biotechnology, Inc.]; Nrg ECD, MS-272-P [Neomark-
ers]; neurofilaments, 1:2,000, NCL-NF68 and NCL-NF160 [Novocastra
Lab.]; MAP-2, sc-5357 [Santa Cruz Biotechnology, Inc.]). The cells were
washed and incubated with rhodamine- or FITC-conjugated secondary an-
tibodies (1:1,000; Jackson ImmunoResearch Laboratories) and TOTO-3
(1  M, Molecular Probes) for 1 h at 37 C. The cells were viewed with a
confocal argon/krypton laser microscope (model LSM 410; Carl Zeiss Mi-
croImaging, Inc.). Data were collected from stacks of  1- M sections.
Cellular fractionation
Cytoplasmic, particulate, and nuclear fractions were prepared using “Nu-
clear and Cytoplasmic extraction reagents” (Pierce Chemical Co.). Protein
concentrations of each sample were measured by the Bradford method. 40
 g of nuclear, 40  g of particulate, and 120  g of cytoplasmic proteins
were separated on 10% SDS-PAGE, transferred to nitrocellulose mem-
branes (Schleicher & Schuell), and probed with antibodies against Nrg-1-ICD,
histone H1, or eIF5. Apparent molecular mass was estimated by compar-
ing the relative mobility of immunoreactive bands to prestained SDS-PAGE
standards (Low Range; Bio-Rad Laboratories).
Plasmid constructs
Epitope-tagged full-length or truncated forms of NRG- 1a were prepared by
the PCR and cloned into pcDNA3.1/V5/His-TOPO or pcDNA3.1/CT-GFP-
TOPO (Invitrogen). The primer pair for fusing full-length CRD-NRG- 1a to
the HA epitope was 5 -ACCATGTCTGAGGGAGCTGGCGGGAGGT-3 
and 3 -TCATACAGCGTAGTCTGGGACGTCGTATGGGTA-5 . The PCR
primer pair used to fuse full-length NRG-1 a to GFP was 5 -AGCATGGCT-
GAGAAGAAGAAGGAAAAA-3  and 3 -TACAGCAATGGGGTCTTGAT-
TCGTTATTACACT-5 . The PCR primer pair used to fuse the cytoplasmic
domain containing the putative NLS-1 (aa 295–390) to GFP was 5 -ATTA-
TGAAAACCAAGAAACAGAGA-3  and 3 -GACCATTACTCCAGCTGT-
GACTTG-5 . The PCR primer pair used to fuse the cytoplasmic domain
lacking NLS-1 (aa 304–390) to GFP was 5 -ATTATGTTGAATGACCGTT-
TAAGA-3  and 3 -GACCATTACTCCAGCTGTGACTTG-5 . GAL4-VP16
was fused in frame to the COOH terminus of full-length NRG-1 a and was
cloned by the PCR into pcDNA3.1/V5/His-TOPO (Invitrogen). Primer pairs
used for amplification of Gal4-VP16 were 5 -GTATACCCATACCCGC-
CGAAGCTT-3  and 3 -CTTATACTCCACCGTACTCGTCAA-5 ; and for
amplification of NRG- 1a were 5 -ATGGCTGAGAAGAAGAAGGAAA-
AAGAA-3  and 3 -GTATGGGTATACAGCAATGGGGTCTTG-5 . DNA se-
quences were confirmed. Note that in each construct, the COOH terminus
was engineered to retain the IAV sequence of the Nrg-1-ICD-a form be-
cause similar sequences have been implicated in targeting and processing
of other transmembrane growth factors.
Luciferase assay
A 10- g plasmid containing four copies of the Gal4-UAS element fused to
the firefly luciferase coding region (p4Luc from R. Evans, Salk Institute, La
Jolla, CA) was cotransfected into 293T cells with 20  g NRG- 1a-Gal4-
VP16 or 20  g NRG-1-ICD-Gal4DBD and 2  g pcDNA-GFP (used to deter-
mine transfection efficiency). Luciferase activity was measured in lysates
48 h after transfection. Where indicated,  -secretase inhibitors (from D.
Selkoe and M. Wolfe, Harvard Medical School, Boston, MA) were added
for the final 24 h.
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